image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 119.19
-3.08 %
$ 17.4 B
Market Cap
10.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIIB stock under the worst case scenario is HIDDEN Compared to the current market price of 119 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIIB stock under the base case scenario is HIDDEN Compared to the current market price of 119 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIIB stock under the best case scenario is HIDDEN Compared to the current market price of 119 USD, Biogen Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIIB

image
$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
9.68 B REVENUE
-1.62%
5.23 B OPERATING INCOME
149.39%
1.63 B NET INCOME
40.53%
2.88 B OPERATING CASH FLOW
85.85%
-799 M INVESTING CASH FLOW
80.51%
-684 M FINANCING CASH FLOW
-457.80%
2.45 B REVENUE
-0.45%
1.24 B OPERATING INCOME
150.28%
267 M NET INCOME
0.00%
761 M OPERATING CASH FLOW
-18.67%
-18.6 M INVESTING CASH FLOW
98.43%
7.9 M FINANCING CASH FLOW
219.70%
Balance Sheet Biogen Inc.
image
Current Assets 7.46 B
Cash & Short-Term Investments 2.38 B
Receivables 1.4 B
Other Current Assets 3.68 B
Non-Current Assets 20.6 B
Long-Term Investments 560 M
PP&E 3.54 B
Other Non-Current Assets 16.5 B
8.47 %5.01 %13.11 %12.61 %58.80 %Total Assets$28.0b
Current Liabilities 5.53 B
Accounts Payable 424 M
Short-Term Debt 1.75 B
Other Current Liabilities 3.36 B
Non-Current Liabilities 5.8 B
Long-Term Debt 4.88 B
Other Non-Current Liabilities 923 M
3.74 %15.43 %29.61 %43.07 %8.14 %Total Liabilities$11.3b
EFFICIENCY
Earnings Waterfall Biogen Inc.
image
Revenue 9.68 B
Cost Of Revenue 0
Gross Profit 9.68 B
Operating Expenses 4.45 B
Operating Income 5.23 B
Other Expenses 3.6 B
Net Income 1.63 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b010b(4b)5b(4b)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
54.06% OPERATING MARGIN
54.06%
16.87% NET MARGIN
16.87%
9.76% ROE
9.76%
5.82% ROA
5.82%
18.46% ROIC
18.46%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biogen Inc.
image
7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.63 B
Depreciation & Amortization 673 M
Capital Expenditures -360 M
Stock-Based Compensation 291 M
Change in Working Capital -155 M
Others 437 M
Free Cash Flow 2.52 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biogen Inc.
image
Wall Street analysts predict an average 1-year price target for BIIB of $267 , with forecasts ranging from a low of $160 to a high of $342 .
BIIB Lowest Price Target Wall Street Target
160 USD 34.24%
BIIB Average Price Target Wall Street Target
267 USD 123.67%
BIIB Highest Price Target Wall Street Target
342 USD 186.94%
Price
Max Price Target
Min Price Target
Average Price Target
350350300300250250200200150150100100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Biogen Inc.
image
Sold
0-3 MONTHS
1.31 M USD 1
3-6 MONTHS
17.3 K USD 1
6-9 MONTHS
88 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate. zacks.com - 2 weeks ago
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. globenewswire.com - 2 weeks ago
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen's presence in Kendall Square, integrating Biogen's research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments. globenewswire.com - 4 weeks ago
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript) Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody. seekingalpha.com - 1 month ago
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report? Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall? Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024. zacks.com - 1 month ago
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients. zacks.com - 1 month ago
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR. globenewswire.com - 1 month ago
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript) Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodman - Leerink Partners Marc Goodman Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America. seekingalpha.com - 1 month ago
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention. 247wallst.com - 1 month ago
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript) Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 45th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen. seekingalpha.com - 1 month ago
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November. reuters.com - 1 month ago
8. Profile Summary

Biogen Inc. BIIB

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 17.4 B
Dividend Yield 0.00%
Description Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Contact 225 Binney Street, Cambridge, MA, 02142 https://www.biogen.com
IPO Date Sept. 17, 1991
Employees 7605
Officers Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs Ms. Robin C. Kramer Executive Vice President & Chief Financial Officer Mr. Adam Keeney Ph.D. Executive Vice President & Head of Corporate Development Mr. Sean Godbout Chief Accounting Officer & Global Corporate Controller Mr. Tim Power M.B.A., Ph.D. Head of Investor Relations Dr. Ginger Gregory Ph.D. Executive Vice President & Chief Human Resources Officer Ms. Susan H. Alexander Esq. Executive Vice President & Chief Legal Officer Mr. Rachid Izzar Executive Vice President and Head of Global Product Strategy & Commercialization Ms. Nicole Murphy Executive Vice President and Head of Pharmaceutical Operations & Technology Mr. Christopher A. Viehbacher President, Chief Executive Officer & Director